Topline data were announced from a phase 3 trial evaluating gefurulimab in adults with anti-acetylcholine receptor antibody-positive generalised myasthenia gravis.

Patients with self-perceived gluten sensitivity and IBS reacted similarly to wheat, gluten, and sham cereal bars.

Weight loss-induced sex hormone changes had a mediating effect on bone mineral density loss among patients with type 2 diabetes.